CR6964A - Combinacion de agonistas de gaba einhibidores de sorbitol-deshidrogenasa - Google Patents
Combinacion de agonistas de gaba einhibidores de sorbitol-deshidrogenasaInfo
- Publication number
- CR6964A CR6964A CR6964A CR6964A CR6964A CR 6964 A CR6964 A CR 6964A CR 6964 A CR6964 A CR 6964A CR 6964 A CR6964 A CR 6964A CR 6964 A CR6964 A CR 6964A
- Authority
- CR
- Costa Rica
- Prior art keywords
- diabetic
- prodrug
- combinations
- einhibitors
- deshidrogenasa
- Prior art date
Links
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 title abstract 3
- 239000000651 prodrug Substances 0.000 abstract 4
- 229940002612 prodrug Drugs 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 abstract 1
- 206010063547 Diabetic macroangiopathy Diseases 0.000 abstract 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 201000009101 diabetic angiopathy Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 231100000397 ulcer Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se refiere a composiciones farmaceuticas que comprenden combinaciones de un agonista de GABA un profarmaco del mismo o una sal farmaceuticamente aceptable de dicho agonista de GABA o dicho profarmaco y un SDI, un profarmaco del mismo o una sal farmaceuticamente aceptable de dicho SDI o dicho profarmaco, estuches que contienen tales combinaciones y metodos para utilizar tales combinaciones en el tratamiento de mamiferos, incluidos los seres humanos, que, padecen complicaciones de la diabetes tales como neuropatia diabetica, nefropatia diabetica, cardiomiopatia diabetica, retinopatia diabetica, microangiopatia diabetica, macroangiopatia diabetica, caratas o ulceras en los pies.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25006900P | 2000-11-30 | 2000-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR6964A true CR6964A (es) | 2004-02-02 |
Family
ID=22946187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR6964A CR6964A (es) | 2000-11-30 | 2003-04-24 | Combinacion de agonistas de gaba einhibidores de sorbitol-deshidrogenasa |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US6544998B2 (es) |
| EP (1) | EP1337271B1 (es) |
| JP (1) | JP2004514699A (es) |
| KR (1) | KR20030059290A (es) |
| CN (1) | CN1477975A (es) |
| AP (1) | AP2001002360A0 (es) |
| AR (1) | AR031431A1 (es) |
| AT (1) | ATE281181T1 (es) |
| AU (1) | AU2002215159A1 (es) |
| BG (1) | BG107774A (es) |
| BR (1) | BR0115783A (es) |
| CA (1) | CA2430298A1 (es) |
| CR (1) | CR6964A (es) |
| CZ (1) | CZ20031399A3 (es) |
| DE (1) | DE60106968T2 (es) |
| DO (1) | DOP2001000289A (es) |
| EA (1) | EA200300432A1 (es) |
| EC (1) | ECSP034624A (es) |
| EE (1) | EE200300248A (es) |
| ES (1) | ES2230378T3 (es) |
| HR (1) | HRP20030420A2 (es) |
| HU (1) | HUP0302160A3 (es) |
| IL (1) | IL155704A0 (es) |
| IS (1) | IS6786A (es) |
| MA (1) | MA26964A1 (es) |
| MX (1) | MXPA03004870A (es) |
| NO (1) | NO20032441L (es) |
| OA (1) | OA12534A (es) |
| PA (1) | PA8534101A1 (es) |
| PE (1) | PE20020597A1 (es) |
| PL (1) | PL365927A1 (es) |
| PT (1) | PT1337271E (es) |
| SK (1) | SK6192003A3 (es) |
| SV (1) | SV2003000751A (es) |
| TN (1) | TNSN01169A1 (es) |
| UY (1) | UY27042A1 (es) |
| WO (1) | WO2002043762A2 (es) |
| ZA (1) | ZA200303381B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0934061B3 (en) | 1996-07-24 | 2015-01-21 | Warner-Lambert Company LLC | Isobutylgaba and its derivatives for the treatment of pain |
| US6992109B1 (en) * | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
| US7022678B2 (en) * | 2001-03-30 | 2006-04-04 | Warner-Lambert Company | Pregabalin lactose conjugates |
| ES2265040T3 (es) | 2001-05-25 | 2007-02-01 | Warner-Lambert Company Llc | Composicion farmaceutica liquida. |
| CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| KR20050036195A (ko) * | 2003-10-15 | 2005-04-20 | 고재영 | 신규한 망막병증 치료제 조성물 |
| US20050220873A1 (en) * | 2004-04-02 | 2005-10-06 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist |
| MXPA06011322A (es) * | 2004-04-02 | 2007-02-21 | Impax Laboratories Inc | Formas de dosificacion farmaceutica que tienen propiedades de liberacion inmediata y/o liberacion controlada que contienen un agonista del receptor gabab. |
| US8007827B2 (en) * | 2004-04-02 | 2011-08-30 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties |
| US20050226927A1 (en) * | 2004-04-02 | 2005-10-13 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist |
| GB0420831D0 (en) | 2004-09-17 | 2004-10-20 | Glaxo Group Ltd | Novel compounds |
| MX2007010076A (es) | 2005-02-17 | 2007-10-16 | Astellas Pharma Inc | Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo. |
| GB0513553D0 (en) * | 2005-07-01 | 2005-08-10 | Fond D Amico Per La Ricerca Su | Rab3a |
| EP2142529B1 (en) * | 2007-04-27 | 2013-12-25 | Purdue Pharma LP | Trpv1 antagonists and uses thereof |
| US20100279984A1 (en) * | 2007-10-09 | 2010-11-04 | Merck Patent Gmbh | Pharmaceutical compositions containing benfotiamine and one or one more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin |
| SG157299A1 (en) | 2008-05-09 | 2009-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| WO2011071995A2 (en) | 2009-12-08 | 2011-06-16 | Case Western Reserve University | Compounds and methods of treating ocular disorders |
| CN107050456B (zh) * | 2010-09-28 | 2022-08-12 | 加利福尼亚大学董事会 | 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合 |
| RS55701B1 (sr) | 2011-06-22 | 2017-07-31 | Purdue Pharma Lp | Trpv1 antagonisti koji uključuju dihidroksi supstituent i njihove upotrebe |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| KR20220008824A (ko) | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
| MX2021013511A (es) * | 2019-05-07 | 2022-02-23 | Univ Miami | Tratamiento y deteccion de neuropatias heredadas y trastornos asociados. |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2409754A (en) | 1946-10-22 | Method for obtaining hydantoins | ||
| CH449645A (de) | 1963-07-09 | 1968-01-15 | Ciba Geigy | Verfahren zur Herstellung neuer Aminosäuren |
| CH427803A (de) | 1963-12-06 | 1967-01-15 | Geigy Ag J R | Verfahren zur Herstellung eines neuen Isoxazolderivates |
| DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US3960927A (en) | 1975-03-18 | 1976-06-01 | Richardson-Merrell Inc. | Olefinic derivatives of amino acids |
| FR2319338A1 (fr) * | 1975-08-01 | 1977-02-25 | Synthelabo | Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent |
| PL124029B1 (en) | 1979-06-01 | 1982-12-31 | Wellcome Found | Process for preparing novel derivatives of 1,2,4-triazine |
| FR2492258A1 (fr) * | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
| US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
| DK288385D0 (da) | 1985-06-26 | 1985-06-26 | Novo Industri As | Aminosyrederivater |
| US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
| WO1994007867A1 (en) * | 1992-09-28 | 1994-04-14 | Pfizer Inc. | Substituted pyrimidines for control of diabetic complications |
| WO2000050034A1 (en) * | 1999-02-24 | 2000-08-31 | The Regents Of The University Of California | Gaba receptors mediate inhibition of t cell responses |
| PL350884A1 (en) * | 1999-04-01 | 2003-02-10 | Pfizer Prod Inc | Aminopyrimidines as sorbitol dehydrogenase inhibitors |
| ATE264311T1 (de) * | 1999-04-01 | 2004-04-15 | Pfizer Prod Inc | Verbindungen zur behandlung und vorsorge bei diabetes |
-
2001
- 2001-11-19 KR KR10-2003-7007237A patent/KR20030059290A/ko not_active Ceased
- 2001-11-19 DO DO2001000289A patent/DOP2001000289A/es unknown
- 2001-11-19 SK SK619-2003A patent/SK6192003A3/sk unknown
- 2001-11-19 OA OA1200300142A patent/OA12534A/en unknown
- 2001-11-19 CA CA002430298A patent/CA2430298A1/en not_active Abandoned
- 2001-11-19 CZ CZ20031399A patent/CZ20031399A3/cs unknown
- 2001-11-19 MX MXPA03004870A patent/MXPA03004870A/es unknown
- 2001-11-19 PT PT01983739T patent/PT1337271E/pt unknown
- 2001-11-19 AT AT01983739T patent/ATE281181T1/de not_active IP Right Cessation
- 2001-11-19 HU HU0302160A patent/HUP0302160A3/hu unknown
- 2001-11-19 ES ES01983739T patent/ES2230378T3/es not_active Expired - Lifetime
- 2001-11-19 EE EEP200300248A patent/EE200300248A/xx unknown
- 2001-11-19 AP APAP/P/2001/002360A patent/AP2001002360A0/en unknown
- 2001-11-19 JP JP2002545732A patent/JP2004514699A/ja not_active Withdrawn
- 2001-11-19 IL IL15570401A patent/IL155704A0/xx unknown
- 2001-11-19 WO PCT/IB2001/002213 patent/WO2002043762A2/en not_active Ceased
- 2001-11-19 EP EP01983739A patent/EP1337271B1/en not_active Expired - Lifetime
- 2001-11-19 AU AU2002215159A patent/AU2002215159A1/en not_active Abandoned
- 2001-11-19 DE DE60106968T patent/DE60106968T2/de not_active Expired - Fee Related
- 2001-11-19 HR HR20030420A patent/HRP20030420A2/hr not_active Application Discontinuation
- 2001-11-19 BR BR0115783-3A patent/BR0115783A/pt not_active IP Right Cessation
- 2001-11-19 PL PL01365927A patent/PL365927A1/xx not_active Application Discontinuation
- 2001-11-19 CN CNA018195946A patent/CN1477975A/zh active Pending
- 2001-11-19 EA EA200300432A patent/EA200300432A1/ru unknown
- 2001-11-27 UY UY27042A patent/UY27042A1/es not_active Application Discontinuation
- 2001-11-28 PE PE2001001191A patent/PE20020597A1/es not_active Application Discontinuation
- 2001-11-28 AR ARP010105541A patent/AR031431A1/es unknown
- 2001-11-29 TN TNTNSN01169A patent/TNSN01169A1/fr unknown
- 2001-11-29 SV SV2001000751A patent/SV2003000751A/es unknown
- 2001-11-29 US US09/997,038 patent/US6544998B2/en not_active Expired - Fee Related
- 2001-11-30 PA PA20018534101A patent/PA8534101A1/es unknown
-
2003
- 2003-04-14 IS IS6786A patent/IS6786A/is unknown
- 2003-04-24 CR CR6964A patent/CR6964A/es not_active Application Discontinuation
- 2003-04-30 ZA ZA200303381A patent/ZA200303381B/en unknown
- 2003-05-07 BG BG107774A patent/BG107774A/xx unknown
- 2003-05-20 MA MA27165A patent/MA26964A1/fr unknown
- 2003-05-27 EC EC2003004624A patent/ECSP034624A/es unknown
- 2003-05-28 NO NO20032441A patent/NO20032441L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR031431A1 (es) | Combinacion de agonistas de gaba e inhibidores de sorbitol-deshidrogenasa | |
| AR031432A1 (es) | Combinacion de agonistas de gaba e inhibidores de aldosa-reductasa | |
| AR067347A1 (es) | Combinacion antihelmintica | |
| MX2021004999A (es) | Administracion de butirato, beta-hidroxibutirato, cannabidiol y compuestos relacionaods en seres humanos. | |
| ECSP23095307A (es) | Agonista del receptor de glp-1 y composición y uso del mismo | |
| AR025329A1 (es) | Tratamiento medicamentoso del sindrome de piernas inquietas | |
| CL2011000835A1 (es) | Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras. | |
| CR11849A (es) | Agonistas mezclados, basados en gip para el tratamiento de trastornos metabólicos y obesidad | |
| CR11418A (es) | Trans-clomifeno para el sindrome metabolico | |
| CL2010000188A1 (es) | Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso. | |
| GT200500173A (es) | Compuestos de heteroaril- y fenilsulfamoilo sustituidos | |
| DOP2012000132A (es) | Composicion farmaceutica que comprende un agonista de glp-1 y metionina | |
| CL2008003576A1 (es) | Compuestos derivados de amida del acido 6,7-dihidro-5h-imidazo[1,2-alfa]imidazol-3-carboxilico; composicion farmaceutica que los comprende; y usos en el tratamiento de una afeccion inflamatoria. | |
| SV2006002100A (es) | Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos ref. p-sv-78.159/msu | |
| ATE348630T1 (de) | Verminderung der nebenwirkungen der chemotherapie in krebspatienten | |
| PA8515601A1 (es) | El uso de composiciones a base de antibioticos de azalidos para tratar o prevenir una infeccion bacteriana o protozoaria en mamiferos | |
| ES2581331T3 (es) | Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática | |
| AR033596A1 (es) | Composicion farmaceutica para inyeccion intramuscular que contiene loxoprofeno | |
| ES2325291A1 (es) | "uso de un extracto de silybum marianum" | |
| AR043016A2 (es) | Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene | |
| AR073086A1 (es) | Composicion farmaceutica para el tratamiento de un trastorno de ansiedad que comprende exo-7-(8-h-8-aza-biciclo(3,2,1)oct-3-iloxi)-cromen-2-ona, uso y equipo | |
| AR029557A1 (es) | Composicion para el uso en el tratamiento o la prevencion de la mastitis, y uso de oxazolidinona para la fabricacion de un medicamento para el tratamiento o la prevencion de la mastitis | |
| ES2477877T3 (es) | Uso de 25-hidroxi vitamina D3 para incrementar la masa muscular en mamíferos | |
| AR061046A1 (es) | Mirtazapina para el tratamiento del dolor neuropatico | |
| AR048355A1 (es) | Asociacion entre un compuesto heterociclico y un agente antioxidante y las composiciones farmaceuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |